Array wrestles FDA OK for its MEK/BRAF melanoma combo, to hit the pharmacy as Mektovi and Braftovi

Just a few weeks after turning up at ASCO with positive data to show off, Array BioPharma $ARRY has nailed an FDA approval for its MEK inhibitor binimetinib, which will be sold as Mektovi, as well as encorafenib — a BRAF inhibitor now dubbed Braftovi.